Catching up with Merck in adjuvant melanoma, Bristol Myers burnishes Opdivo profile in earlier stages of cancer
Melanoma was the first cancer type for which Bristol Myers Squibb’s Opdivo scored an FDA approval. And the pharma giant is still trying to reach …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
